-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Underweight on GoodRx Holdings, Raises Price Target to $4

Benzinga·08/21/2026 15:07:06
Listen to the news
Barclays analyst Glen Santangelo maintains GoodRx Holdings (NASDAQ:GDRX) with a Underweight and raises the price target from $3 to $4.